106 related articles for article (PubMed ID: 22745146)
1. Acute liver failure related to chemotherapy.
Wijaya I; Sanityoso A; Lesmana LA
Acta Med Indones; 2012 Apr; 44(2):145-9. PubMed ID: 22745146
[TBL] [Abstract][Full Text] [Related]
2. Fatal reactivation of hepatitis B after chemotherapy for lymphoma.
Dillon R; Hirschfield GM; Allison ME; Rege KP
BMJ; 2008 Jul; 337():a423. PubMed ID: 18595895
[No Abstract] [Full Text] [Related]
3. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.
Stange MA; Tutarel O; Pischke S; Schneider A; Strassburg CP; Becker T; Barg-Hock H; Bastürk M; Wursthorn K; Cornberg M; Ott M; Greten TF; Manns MP; Wedemeyer H
Z Gastroenterol; 2010 Feb; 48(2):258-63. PubMed ID: 20127601
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
5. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.
Zurawska U; Hicks LK; Woo G; Bell CM; Krahn M; Chan KK; Feld JJ
J Clin Oncol; 2012 Sep; 30(26):3167-73. PubMed ID: 22711851
[TBL] [Abstract][Full Text] [Related]
8. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
[TBL] [Abstract][Full Text] [Related]
10. Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus.
Ohmoto K; Tsuduki M; Yamamoto S
Am J Gastroenterol; 2003 May; 98(5):1215-6; author reply 1217. PubMed ID: 12809863
[No Abstract] [Full Text] [Related]
11. Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy.
Shimizu D; Nomura K; Matsumoto Y; Ueda K; Yamaguchi K; Minami M; Itoh Y; Horiike S; Morita M; Taniwaki M; Okanoue T
World J Gastroenterol; 2004 Aug; 10(15):2301-2. PubMed ID: 15259089
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.
Koo YX; Tan DS; Tan BH; Quek R; Tao M; Lim ST
J Clin Oncol; 2009 May; 27(15):2570-1; author reply 2571-2. PubMed ID: 19364951
[No Abstract] [Full Text] [Related]
13. [Effective treatment with Lamivudine of patients with reactivation of hepatitis B following chemotherapy administration].
Shtalrid M; Haran M; Klepfish A; Lurie Y; Malnick S
Harefuah; 2001 Dec; 140(12):1159-62, 1230, 1229. PubMed ID: 11789300
[TBL] [Abstract][Full Text] [Related]
14. Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma.
Sato T; Kato J; Kawanishi J; Kogawa K; Ohya M; Sakamaki S; Niitsu Y
J Gastroenterol; 1997 Oct; 32(5):668-71. PubMed ID: 9349995
[TBL] [Abstract][Full Text] [Related]
15. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
[TBL] [Abstract][Full Text] [Related]
16. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma.
Wasmuth JC; Fischer HP; Sauerbruch T; Dumoulin FL
Eur J Med Res; 2008 Oct; 13(10):483-6. PubMed ID: 19008178
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
[TBL] [Abstract][Full Text] [Related]
18. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
[TBL] [Abstract][Full Text] [Related]
19. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Muñoz Bertrán E; Pérez Ceballos E; Gómez Espín R; Ortega González I
Gastroenterol Hepatol; 2010 May; 33(5):377-81. PubMed ID: 20363054
[TBL] [Abstract][Full Text] [Related]
20. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.
Law JK; Ho JK; Hoskins PJ; Erb SR; Steinbrecher UP; Yoshida EM
Leuk Lymphoma; 2005 Jul; 46(7):1085-9. PubMed ID: 16019563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
